About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 3NCT00471146

Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

The purpose of this study is to determine whether investigational study drug, AG-013736, and gemcitabine are effective in the first-line treatment of advanced pancreatic cancer.

Lead sponsor: Pfizer•77 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Pfizer

This study was prematurely discontinued for futility on 23 January 2009, based on a planned interim analysis by an independent Data Safety Monitoring Board (DSMB) that found no evidence of improvement in the primary endpoint (survival) in patients treated with axitinib and gemcitabine compared to gemcitabine alone. Enrollment on this study has been discontinued.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Histologically or cytologically confirmed, metastatic or locally-, advanced pancreatic adenocarcinoma not amenable to curative resection.
•Adequate renal, hepatic and bone marrow function.
•Performance status 0 or 1.

Exclusion Criteria

•Prior treatment with any systemic chemotherapy for metastatic disease.
•Prior treatment with gemcitabine, AG-013736, or other vascular endothelial growth factor inhibitors.
•Current or recent bleeding, thromboembolic event and or use of a thrombolytic agent.
•Inability to take oral medication.

Related studies

RECRUITINGPhase 2

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07259317 · Adenocarcinoma, Carcinoma, Pancreatic Ductal

TERMINATEDPhase 1

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

NCT06704724 · Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, and more

TERMINATEDPhase 1

A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

NCT06974734 · Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, and more

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

NCT05461430 · Pleural Effusion, Malignant, Ascites, Malignant, and more

Study of Changes and Characteristics of Genes in Patients With Pancreatic Cancer for Better Treatment Selection

NCT02750657 · Carcinoma, Pancreatic Ductal

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 16, 2012Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment630

Start dateJul 2007

Last updatedJul 16, 2012

Condition

Carcinoma, Pancreatic Ductal

Locations shown

Pfizer Investigational Site

Antioch, California

Pfizer Investigational Site

Corona, California

Pfizer Investigational Site

Glendora, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 16, 2012Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions